Case Study: Bcl-6 and Its Relationship to Diffuse Large B-Cell Lymphoma
The following case study focuses on bcl-6 and its relationship to
diffuse large B-cell lymphoma (DLBCL). Test your knowledge by reading
the question below and making the proper selection.
All of the following are true regarding bcl-6 and its relationship to DLBCL except (select one):
- Bcl-6 is the most commonly involved oncogene in DLBCL.
- Bcl-6 positivity is associated with a favorable prognosis in DLBCL.
- Approximately one-quarter of DLBCLs are bcl-6 negative.
positive DLBCL seems to derive a therapeutic benefit from the addition
of Rituxan to CHOP chemotherapy not seen in bcl-6 negative DLBCL.
- Bcl-6 expression is closely linked to the germinal-center phenotype as characterized by gene expression profiling.
- Bcl-6 positive DLBCL seems to derive a
therapeutic benefit from the addition of Rituxan to CHOP chemotherapy
not seen in bcl-6 negative DLBCL.
Gene expression profiling has identified at least three clinically
relevant phenotypes of DLBCL, which include germinal-center type,
activated B-cell type, and mediastinal large B-cell lymphoma1.
bcl-6, a marker of germinal center derivation, has been identified as a
characteristic protein expressed in many, but not all, germinal-center
type DLBCLs. It is the most commonly involved oncogene in DLBCL and
confers a more favorable prognosis in DLBCL treated with conventional
anthracycline-based chemotherapy2,3. Recently, an ECOG/SWOG
Intergroup trial comparing CHOP to CHOP-R looked prospectively at bcl-6
expression in DLBCL. Prospective data showed that treatment with
Rituximab in addition to standard CHOP chemotherapy improved survival
in patients with bcl-6 negative disease but not with bcl-6 positive
disease making overall outcomes similar in both populations4.
Further correlative studies will help clarify prognostic indicators in
the context of new therapeutic regimens. At the current time, gene
expression profiling is not routinely done in the clinic but rather as
an adjunct to clinical trials.
- Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-11.
- Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation
of the molecular classification of diffuse large B-cell lymphoma by
immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-82.
- Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937-47.
- Winter JN, Weller EA, Horning SJ, et al. Prognostic significance of BCL-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood. 2006;107(11):4207-13.
Armitage J. How I treat patients with diffuse large B-cell lymphoma. Blood. 2007;110(1):29-36.
Case study submitted by Lanie Kasdan Francis, MD, of the
University of Pittsburgh Medical Center and Christine Chen, MD, of
Princess Margaret Hospital in Toronto.
back to top